T0	KEYPHRASE-NOTYPES 0 9	Treatment
T1	KEYPHRASE-NOTYPES 14 22	patients
T2	KEYPHRASE-NOTYPES 28 44	erythema migrans
T3	KEYPHRASE-NOTYPES 64 80	oral doxycycline
T4	KEYPHRASE-NOTYPES 84 95	amoxicillin
T5	KEYPHRASE-NOTYPES 112 120	patients
T6	KEYPHRASE-NOTYPES 150 156	agents
T7	KEYPHRASE-NOTYPES 161 176	local infection
T8	KEYPHRASE-NOTYPES 185 203	excellent response
T9	KEYPHRASE-NOTYPES 222 230	patients
T10	KEYPHRASE-NOTYPES 237 253	oral antibiotics
T11	KEYPHRASE-NOTYPES 258 271	early disease
T12	KEYPHRASE-NOTYPES 279 296	favorable outcome
T13	KEYPHRASE-NOTYPES 324 329	drugs
T14	KEYPHRASE-NOTYPES 335 356	insufficient activity
T15	KEYPHRASE-NOTYPES 365 373	borrelia
T16	KEYPHRASE-NOTYPES 381 403	central nervous system
T17	KEYPHRASE-NOTYPES 410 421	Ceftriaxone
T18	KEYPHRASE-NOTYPES 447 448	B
T19	KEYPHRASE-NOTYPES 474 485	high levels
T20	KEYPHRASE-NOTYPES 493 512	cerebrospinal fluid
T21	KEYPHRASE-NOTYPES 517 531	synovial fluid
T22	KEYPHRASE-NOTYPES 541 550	Treatment
T23	KEYPHRASE-NOTYPES 556 567	ceftriaxone
T24	KEYPHRASE-NOTYPES 603 615	Lyme disease
T25	KEYPHRASE-NOTYPES 646 662	neuroborreliosis
T26	KEYPHRASE-NOTYPES 664 672	carditis
T27	KEYPHRASE-NOTYPES 678 688	meningitis
T28	KEYPHRASE-NOTYPES 713 718	study
T29	KEYPHRASE-NOTYPES 734 747	effectiveness
T30	KEYPHRASE-NOTYPES 752 764	tolerability
T31	KEYPHRASE-NOTYPES 768 790	parenteral ceftriaxone
T32	KEYPHRASE-NOTYPES 795 816	standard oral therapy
T33	KEYPHRASE-NOTYPES 820 828	patients
T34	KEYPHRASE-NOTYPES 853 854	B
T35	KEYPHRASE-NOTYPES 868 877	infection
T36	KEYPHRASE-NOTYPES 890 900	meningitis
